152 unknown, 150 recruiting, 85 not yet recruiting, 48 completed. 354 Phase 2, 124 Phase 1, 56 Phase 3, 15 Not applicable, 5 Early Phase 1.
Follow toripalimab: new trials by email Literature Review of toripalimab trials Research Report on toripalimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 20 | 2027-01-01 | 2026-10-01 |
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel - Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | 150 | 2026-10-20 | 2026-10-16 |
| JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer JS207, JS007, Toripalimab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 560 | 2026-10-08 | 2026-09-16 |
| Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT Toripalimab (JS001 ), Gemcitabine (GEM) - Non Muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Tianjin First Central Hospital | 54 | 2026-10-01 | 2026-09-08 |
| Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC Toripalimab, Sacituzumab Tirumotecan (SKB264) - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Shaodong Hong | 30 | 2026-10-01 | 2026-09-15 |
| Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma Sacituzumab tirumotecan, Toripalimab - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 33 | 2026-10-01 | 2026-09-16 |
| Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-09-17 |
| Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status Toripalimab, Paclitaxel - Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Phase 2 | Not yet recruiting | Barbara Ann Karmanos Cancer Institute | 22 | 2026-09-30 | 2026-08-31 |
| MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-09-20 | 2026-09-14 |
| Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer Cryo-Thermal Ablation, Toripalimab, Platinum-based doublet chemotherapy - Carcinoma, Non-Small-Cell Lung (NSCLC) | Phase 2 | Recruiting | West China Hospital | 40 | 2026-09-10 | 2026-10-02 |
| A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure Intravesical Instillation of Disitamab Vedotin Combined with Toripalimab - Bladder Cancer | Phase 1 | Not yet recruiting | Xiangya Hospital of Central South University | 20 | 2026-09-01 | 2026-08-25 |
| SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma Toripalimab, Liposomal doxorubicin, Stereotactic body radiotherapy (SBRT) - Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 39 | 2026-09-01 | 2026-09-14 |
| Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases Dupilumab, Toripalimab - Metastatic Colorectal Cancer, Liver Metastases | Phase 1 / Phase 2 | Recruiting | Dan Feng | 24 | 2026-09-01 | 2026-08-12 |
| A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma Sacituzumab Govitecan OR Sacituzumab Tirumotecan in Combination with Toripalimab, Radical Surgery for OSCC, Radiation Therapy - Oral Squamous Cell Carcinoma (OSCC) | Phase 2 | Not yet recruiting | Shanghai East Hospital | 20 | 2026-09-01 | 2026-08-21 |
| TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-08-20 | 2026-08-20 |
| A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. DXC006, Toripalimab, Carboplatin - Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Hangzhou DAC Biotechnology Co., Ltd. | 200 | 2026-08-19 | 2026-09-24 |
| SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma axitinib plus toripalimab, SABR - Oligometastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 48 | 2026-08-15 | 2026-08-04 |
Showing 20 of 490. Sign in to see all of them.
Nasopharyngeal Carcinoma (40) · Carcinoma, Non-Small-Cell Lung (35) · Esophageal Squamous Cell Carcinoma (26) · Carcinoma, Hepatocellular (24) · Squamous Cell Carcinoma of Head and Neck (21) · Triple Negative Breast Neoplasms (19) · Breast Neoplasms (18) · Melanoma (15) · Carcinoma, Renal Cell (14) · Stomach Neoplasms (14) · Colorectal Neoplasms (13) · Small Cell Lung Carcinoma (13) · Carcinoma, Transitional Cell (12) · Uterine Cervical Neoplasms (12) · Neoplasms (11)
Sun Yat-sen University (59) · Shanghai Junshi Bioscience Co., Ltd. (29) · Fudan University (27) · Tianjin Medical University Cancer Institute and Hospital (17) · Peking Union Medical College Hospital (11) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (10) · Shanghai Pulmonary Hospital, Shanghai, China (10) · Henan Cancer Hospital (9) · Peking University (9) · RemeGen Co., Ltd. (9) · First Affiliated Hospital of Zhejiang University (8) · Coherus Oncology, Inc. (7) · LaNova Medicines Limited (7) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (7) · West China Hospital (7)
China (395) · United States (22) · Australia (9) · Taiwan (4) · Canada (3) · Singapore (2) · Armenia (1) · Austria (1) · Georgia (1) · Hong Kong (1) · Netherlands (1) · South Korea (1) · Spain (1) · Turkey (Türkiye) (1)
Lin Shen (5) · Jianmin Fang, Ph.D (4) · Funan Liu, MD (3) · Jiren Yu (3) · Liangrong Shi, M.D. (3) · Sheng Yao, PhD (3) · Zhenning Wang, MD (3) · Baiyong Shen (2) · Dan Feng, MD, PhD (2) · Haitao Zhao, MD (2) · Hui Liu, Professor (2) · Jun Tang, MD (2) · Lin Shen, Professor (2) · Mian Xi, MD (2)
PMID 30642373, PMID 36990609, PMID 19188168, PMID 30207593, PMID 31150573, PMID 34341578, PMID 35623069, PMID 41423415, PMID 11224527, PMID 11251976, PMID 11574279, PMID 14525967, PMID 15629599, PMID 16110319, PMID 16382236, PMID 16530813, PMID 16682732, PMID 17103253, PMID 17195077, PMID 18173375, PMID 18430910, PMID 19171491, PMID 19564532, PMID 19801930, PMID 19934295, PMID 20354531, PMID 20373055, PMID 20375404, PMID 20436836, PMID 20516446, PMID 20956625, PMID 21240983, PMID 21514072, PMID 22178121, PMID 22646630, PMID 22658127, PMID 23393121, PMID 23421934, PMID 23484057, PMID 23510863, PMID 23552472, PMID 23578724, PMID 23724846, PMID 23749461, PMID 23981851, PMID 23991649, PMID 24403232, PMID 24474817, PMID 24520205, PMID 24769639
P30CA014089 (1), P30CA138292 (1)